A matrix metalloproteinase inhibitor, ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit

International Heart Journal

Volumn 48, Issue 3, 2007, Pages 369-378

  Okamoto, Yasuhiro ^a   Satonura, Kimio ^a   Nakayama, Kazuhiro ^a   Tanaka, Nobukiyo ^a   Ohsuzu, Fumitaka ^a   Imaki, Junko ^a   Yoshioka, Masahiko ^a   Nakamura, Haruo ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Mitsukoshi Health and Welfare Foundation   (Japan)

Author keywords

Atherosclerosis; Extracellular matrix; Matrix metalloproteinase; ONO 4817

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; CHOLESTEROL; GELATINASE A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA INTIMA; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LOCALIZATION; HISTOLOGY; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER;

ANIMALS; AORTA; AORTIC DISEASES; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; HYPERLIPIDEMIAS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASES; PHENYL ETHERS; RABBITS; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 34547553563     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.369     Document Type: Article

References (21)

1. Galis ZS, Sukhova GY, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-503.
2. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88: 8154-8.
3. Brown DL, Hibbs MS, Keamey M, Loushin C, Isner JM, Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125-31.
4. Ambrose JA, Martinez EE, A new paradigm of plaque stabilization. Circulation 2002; 105:2000-4.
5. Celentano DC, Frishman WH. Matrix metalloproteinases and coronary artery disease: a novel therapeutic target. J Clin Pharmacol 1997; 37:991-1000. (Review)
6. George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 2000; 9:993-1007. (Review)
7. Prescott W, Sawyer WK, Von Linden-Road, JV, et al. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann N Y Acad Sci 1999; 878:179-90.
8. Cherr GS, Motew SJ, Travis JA, et al. Metalloproteinase inhibition and response to angioplasty and stenting in atherosclerotic primates. Arterioscler Thromb Vasc Biol 2002; 22: 161-6.
9. Jhonson JL, Fritsche-Danielson R, Behrendt M, et al. Effect of broad-spectrum matrix metalloproteinase inhbition on atherosclerotic plaque stability. Cardiovasc Res 2006; 71:586-95.
10. Yamada A, Uegaki A, Nakamura T, Ogawa, K, ONO-4817, an orally active matrix metalloprotainase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res 2000; 49:144-6.
11. Muraishi Y, Mitani N, Fuse H, Saiki I. Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma. Anticancer Res 2001; 21: 3845-52.
12. Sawada, S, Murakami K, Yamaura T, Mitani N, Tsukada, Y, Saiki I. Therapeutic and analysis model of intrahepatic metastasis reflects clinical behavior of hepatocellular carcinoma. Jpn J Cancer Res 2002; 93: 190-7.
13. Shiraga M, Yano S, Yamamoto A, et al. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res 2002; 62: 5967-73.
14. Yamashita T, Fujii M, Tomita T, et al. The inhibitory effect of matrix metalloptoteinase inhibitor ONO-4817 on lymph node metastasis in tongue carcinoma. Anticancer Res 2003; 23: 2297-302.
15. Yamamoto A, Yano S, Shiraga, M, Ogawa H, Goto H, Miki T, Zhang H, Sone S. A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in mude mice. Int J Cancer 2003; 103: 822-8.
16. Matsuno H, Ishisaki A, Nakajima, K, Kozawa O. Effect of a synthetic matrix metalloproteinase inhibitor (ONO-4817) on neointima formation in hypercholesterolemic hamsters. J Cardiovas Pharmacol 2004; 44: 57-65.
17. Hariya A, Takazawa Y, Yamamoto T, Amano A. ONO-4817, a novel matrix metalloproteinase inhibitor, attenuates allograft vasculopathy in a rat cardiac transplant. J Heart Lung Transplant 2004; 23: 1163-9.
18. Okamoto Y, Satomura K, Ohusuzu F, Nakamura, H, Takeuchi Y, Yoshioka M. Expression of matrix metallo-proteinase 3 in experimental atherosclerotic plaques. J Atheroscler Thromb 2001; 8: 50-4.
19. Johnson C, Galis ZS. Matrix metalloproteinases-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004; 24: 54-60.
20. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and artherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90:251-62.
21. Shogo K. Atherosclerotic instability and matrix metalloproteinases. J Jpn Coll Angiol 2003; 43: 699-705.